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Characterization of platelet-activating factor synthesis in glomerular
endothelial cell lines. Platelet-activating factor synthesis in two trans-
formed lines of glomerular endothelial cells was characterized and con-
trasted with platelet-activating factor production in macrovascular-derived
endothelial cells as well as with glomerular cells of mesenchymal origin.
Platelet-activating factor synthesis was assessed in intact cells and in
cell-free preparations. Glomerular endothelial cells constitutively synthe-
size bio-active alkyl-PAF, and this basal activity can be chronically
augmented by various inflammatory and thrombotic agents. In contrast,
thrombin-mediated platelet-activating factor formation in bovine pulmo-
nary aortic endothelial cells as well as in glomerular mesangial cells is
acute and transient. The potential role of anti-inflammatory prostanoids
to function as negative feedback modulators of thrombin- or endothelin-
mediated platelet-activating factor synthesis was also investigated, as the
synthesis of platelet-activating factor is often associated with the forma-
tion of these prostanoids. Indomethacin augmented receptor-mediated
platelet-activating factor synthesis while prostanoids of the E and I series
reduced agonist-stimulated PAF synthesis. In summary, the unique capac-
ity of glomerular endothelial cells to respond to inflammatory stimuli with
sustained platelet-activating factor synthesis is a clear indication of this
cell's pivotal role in augmenting the inflammatory response in the limited
environment of the glomerulus.
Until recently, the role of the endothelium in regulating
glomerular function has been deduced by extrapolating data
derived from other microvascular endothelial cells. With the
advent of techniques that have isolated, characterized and prop-
agated microvascular glomerular endothelial cells (GEC) [1, 2],
we have investigated and contrasted prostanoid metabolism in
bovine GEC and endothelium derived from the macrovasculature
[3]. To maintain the endothelial phenotype in culture, we now
utilize GEC lines transformed with either the simian virus large T
antigen or the adeno virus. Primary cultures of glomerular
endothelial cells have proven to be quite difficult in establishing a
reproducible and propagative endothelial phenotype. Our ap-
proach to this problem has been to use two permanent GEC lines,
transfected through dissimilar procedures. In one case, bovine
GEC primary cultures are transfected with the simian virus large
T antigen and in the second case, rat glomeruli are directly
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infected with the adeno virus and GEC are subsequently selec-
tively cloned. In this way, similar results with these two different
homogenous and antigenically stable cell lines suggest that the
transformation process itself or culturing artifacts are not as
important as the expressed phenotype. As prostanoids and plate-
let-activating factor (PAF), both bioactive lipids, can be derived
through a common phospholipase A2 enzymatic pathway [4], we
now have investigated PAF synthesis induced by inflammatory
and thrombotic agonists in GEC lines with comparisons to
glomerular rat mesangial cells (MC) and bovine pulmonary artery
endothelial cells (BPAEC). The role of prostaglandins to regulate
PAF synthesis in GEC and MC was also investigated.
Vascular endothelial cells synthesize PAF in response to vari-
ous inflammatory agonists including thrombin, histamine and
bradykinin [5]. PAP is a bioactive autocrine lipid that has been
implicated in acute inflammation, anaphylaxis and thrombosis [6].
PAF has been characterized as 1-0-alkyl-2-acetyl-sn-glycero-3-
phosphocholine [7] and can be synthesized through both a remod-
eling pathway (phospholipase A2 and PAF acetyl transferase) as
well as a de novo pathway (choline phosphotransferase) [8]. PAP,
like thrombin, regulates fibrinolysis [9], is a chemo-attractant for
PMN and macrophages [10], activates receptor-GTP-binding pro-
tein-linked phospholipases [11, 12], and induces matrix formation
[13]. PAP may mediate thrombin, histamine or bradykinin-in-
duced acute inflammation or allergic reactions in endothelial cells
as PAF receptor antagonists inhibit histamine- or thrombin-
induced PMN adherence to vascular endothelial cells [14], and
PAP receptor antagonists inhibit thrombus formation and platelet
adherence to endothelium [15]. In addition, platelet/leukocyte
interactions or adherence to endothelial cells is induced by PAP in
vitro [16]. The role of PAP in regulating glomerular function
(modulating glomerular filtration rate, mesangial cell contractility
and glomerular capillary permselectivity) has been reviewed [17,
18]. However, the regulation of thrombin-stimulated and basal
PAP synthesis in GEC has not been investigated.
Thrombin is a serine protease that regulates coagulation and
fibrinolysis. Thrombin increases intravascular and intraglomerular
fibrin formation through both the formation and stabilization of
fibrin [19]. Thrombin also activates high affinity receptors in
endothclium initiating phospholipase C and A2 signaling cascades
associated with mitogenesis, change in shape and matrix forma-
tion. Thrombin stimulates both macro- and microvascular endo-
thelial cells to produce and/or release PAF, prostaglandins, von
1404
Kester et al: PAF synthesis 1405
Willebrand factor, plasminogen-activator inhibitor, cAMP, cGMP
and PDGF. Thrombin increases endothelial permeability, modi-
fies new DNA synthesis and is a chemoattractant for macro-
phages, monocytes and PMN, events associated with glomerular
disease [20]. Also, intrarenal generation of thrombin is associated
with glomerular and/or infiltrating phagocyte expression of throm-
boplastin and prothrombinase. Localized intravascular coagula-
tion has been implicated in a variety of glomerular and renal
vascular diseases including glomerulonephritis, renal allograft
rejection, and hemolytic urenemic syndrome [21]. In addition to a
decreased GFR, there is an increased fibrin deposition in the
glomerulus, an increased release of fibrin degradation products in
the urine, altered fibrinogen metabolism and altered platelet
survival. Although thrombin signaling and function in glomerular
mesangial cells and epithelial cells is well characterized [19], the
relevance of thrombin interactions with GEC remains unknown.
Even though thrombin and PAF interactions in endothelial
cells have been documented, the role of these inflammatoiy
mediators in glomerular microvascular endothelial cells has not
been investigated. Using two separate transformed/immortalized
GEC lines that are well characterized, we now investigate throm-
bin-stimulated PAF synthesis. We have assessed PAF production
in intact cells as well as in cell-free assays that measure PAF-acetyl
transferase and PAF-acetyl hydrolase activities. We demonstrate
that, in contrast to endothelial cells of macrovasculature origin,
PAF synthesis in transformed GEC lines is a constitutive event
that can be chronically stimulated with thrombin for upwards of
24 hours. We also demonstrate that thrombin-stimulated prostan-
oids of the E and I series reduce thrombin-stimulated PAF
synthesis completing a negative feedback ioop regulating PAF
production.
Methods
Materials
Platelet-activating factor (1-0-octadecyl-2-acetyl-sn-glycero-3-
phosphocholine), lyso-platelet-activating factor (1-0-octadecyl-sn-
glycero-3-phosphocholine), and lyophilized human thrombin were
purchased from Calbiochem Corp. (La Jolla, California, USA).
Human endothelin-1 was purchased from Peptides International
(Louisville, Kentucky, USA). The sodium salt of [3H]acetic acid
(475 mCi/mmol) was purchased from ICN Biomedicals, Inc.
(Irvine, California, USA). [3H]PAF (1-0 hexadecyl-2-acetyl-sn-
glycero-3-phosphocholine, 1-0-[acetyl-3H(N)] (10 Ci/mmol) was
purchased from DuPont New England Nuclear Research Prod-
ucts (Boston, Massachusetts, USA). 16,16-Dimethyl prostag-
landin E2 was purchased from Caymen Chemical (Ann Arbor,
Michigan, USA) and iloprost was obtained from Calbiochem.
Bovine pulmonary artery endothelium was purchased from Amer-
ican Type Culture Collection (Rockville, Maryland, USA). Insu-
lin/transferrin/selenium acid (ITS) premix was purchased from
Collaborative Research, Inc. (Bedford, Massachusetts, USA).
Defined bovine calf serum and characterized fetal bovine serum
were purchased from HyClone Laboratories, Inc. (Logan, Utah,
USA). All other reagents were purchased from Sigma Chemical
(St. Louis. Missouri. USA.
Isolation, culture, and transfection of bovine and rat glomerular
endothelial cells
Calf kidneys were utilized to initiate primary bovine GEC
cultures as previously described [2]. Individual cell clones were
characterized morphologically and were examined for angiotensin
I-converting enzyme activity, expression of von Willebrand's
antigen, and uniform uptake of fluorescent acetylated low-density
lipoprotein, as previously described [2, 3]. LDL uptake and von
Willebrand's staining were observed in transformed and untrans-
formed GEC and BPAEC but not MC. The degree of LDL
uptake and von Willebrand's staining in GEC did not change as a
function of transformation. These data, in conjunction with phase
contrast micrographs of GEC, confirmed the endothelial pheno-
type of the transformed cells.
Bovine GEC were transformed with a defective recombinant
retrovirus vector expressing a mutant of simian virus 40 large T
antigen. The U19 mutant of the SV4O large T antigen has been
shown to immortalize rodent fibroblasts and murine stromal cells
while being unable to induce replication of SV4O DNA [22]. The
U19 retrovirus contains SV4O early-region viral sequences from
the Bgll site to the Hpal site cloned into the BamHI site of the
pZip Neo SV(X)1 vector. The U19-5 cell line was created by
transfection of this plasmid. This Psi-2 producer cell line produces
5 x i04 G418 resistance CFU/ml when assayed on rat embryo
fibroblasts. Virus released from U19-5 cells was harvested 18
hours after the addition of fresh medium, as previously described
[22]. Transformation of GEC was initiated 24 hours after passage
of P1 GEC cultures. Fourteen days later, G418-resistant GEC
were selected in 0.5 mg/nil G418. G418-resistant colonies were
isolated at day 28, expanded, characterized, and stored at —70°C.
Untransformed and transformed GEC were cultured in RPMI
1640 medium supplemented with 15% BCS, antibodies and
glutamine.
The second GEC line was cloned from rat kidney glomeruli that
were initially immortalized with an oncogenic adeno 31 virus as
previously described [23]. The resulting GEC line expressed von
Willebrand's antigen, acetylated low density lipoprotein receptors,
podacalyxin and OX-43 anti-rat endothelial cell antibody, but not
anti-thy 1.1 or anti-desmin antibodies that recognize GMC. In
addition, epithelial cell markers, including anti-thrombospondin
and anti-cytokeratin antibodies, failed to bind to the GEC line.
The transformed GEC line did not release any adenoviral protein
by immunoprecipitation nor was the transforming adenoviral EIA
gene found by Southern blotting or PCR amplification analysis.
For comparison, pulmonary artery endothelial cells were pur-
chased from American Type Culture Collection and cultured in
EMEM supplemented with 20% FBS, glutamine and antibiotics.
These heavily passaged macrovascular endothelial cells maintain
the endothelial cell phenotype upon extensive culturing and thus
are a suitable cell for comparison to an "immortalized" glomer-
ular endothelial cell.
Culture and isolation of rat mesangial cells
Glomeruli from Wistar rats (Charles River, Wilmington, Mas-
sachusetts, USA) were isolated by the sequential sieving tech-
nique previously reported [24]. The isolated glomeruli were
partially digested with collagenase to remove epithelial cells and
to form glomerular cores which were resuspended in RPMI 1640
medium containing 20% FBS sunniemented with lutamine.
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penicillin, streptomycin and ITS premix at 37°C in 5% C02195%
air. Primary cultures were incubated for 8 to 10 days and then
subeultured. The mesangial cells exhibited typical morphology
and contractile responses [23].
Assay of [3H]PAF accumulation in intact cells
Confluent cells in Costar 12 well plates were washed with 37°C
Earle's balanced salt solution three times [25]. Earle's solution
was then removed and replaced with 0.6 ml of a buffer containing
1.3 mii CaC12, 20 mrvi HEPES, 0.2% BSA (wt/vol), and 20 sCi!ml
[3H]acetic acid in Earle's balanced salt solution (pH 7.4). Cells
were stimulated immediately with the appropriate agonist. Reac-
tions were stopped with the addition of 1 ml ice-cold acidified
methanol. Wells were scraped and cells transferred to borosilicate
test tubes containing 1 ml chloroform. One milliliter acidified
methanol was again added to each well, rescraped and the
fractions combined (final 1:2:0.8, chloroform/methanol/water, you
vol/vol). Tubes were vortexed and allowed to stand as one phase
for one hour at 25°C. To initiate phase separation, 1 ml water and
1 ml chloroform were added to the 3H-lipids to generate a final
ratio of 1:1:0.9, chloroformJmethanol/H20, vol/vol/vol. This solu-
tion was vortexed and centrifuged for 10 minutes at 2000 g. The
lower layer was extracted and saved while the top layer was
re-extracted with 2 ml chloroform, and then vortexed and centri-
fuged. The two lower chloroform layers containing lipid material
were combined and evaporated to dryness under nitrogen. Lipids
were separated on heat-activated HPTLC plates using a solvent
system comprised of chloroform/methanol/water 65:35:6, vol/you
vol. Standards included 1-0-alkyl-2-lyso glycero phosphocholine,
C-18-PAF, sphingomyelin, PtdCho, and PtdEth which migrated
with Rf values of 0.11, 0.15, 0.18, 0.23 and 0.51, respectively.
Lipids were visualized with toludino-napthol sulfonic acid and UV
light and lipids which comigrated with internal standards were
scraped and counted by liquid scintillation.
Characterization of alkyl- and acyl-PAF species
3H-PAF was extracted and TLC-separated as described above
[26]. The lipid that comigrated with authentic C-18 PAF was
extracted from the silica gel and subjected to derivatization. The
lipid was first digested with 10 units of phospholipase C from
Bacifius cereus and clostridium Welchii for two hours at 37°C in
a mixture of 2 ml of ether and 1 ml of 100 ms Tns HC1
supplemented with 2 mri CaC12, pH 7.5. After evaporation of the
ether layer under N2, the lipids were extracted by Bligh and Dyer
extraction and diglycerides were acetylated in 1 ml of 5:1 acetic
anhydride:pyridine at 25°C for 12 hours. The diglyceride acetates
were extracted three times in 1 ml hexane and then evaporated
and rechromatographed on Silica gel HL plates with an elution
mixture consisting of hexane/ether/acetic acid, 60:40:1, vol/vol/vol.
Diglyceride-acetate standards were prepared from authentic
C18:0 PAP, acyl-PAF, PtdCho and acyl-acetyl glycerol and were
used to identify ailcyl-PAF and acyl-PAF derivatized analogs.
In vitro PAF acetyltransfrrase activity assay
PAP acetyltransferase activity in cell lysates was determined as
described by Billah, Bryant and Siegel [27] and modffied by Villani
et al [28]. Cells were grown to confluency in Costar 6-well plates,
stimulated with the appropriate agonist and washed three times
with an ice-cold buffer containing 250 m sucrose, 0.5 mM EGTA,
1 mM D1T, and 10 nmi HEPES (pH 7.0) (HEPES/sucrose buffer).
Cells were then scraped and resuspended in 2 ml of ice-cold
HEPES/sucrose buffer. The cells were sonicated (sonic dismem-
brator, Artek Systems Corp., Farmingdale, New York, USA) for
15 seconds three times at 4°C and centrifuged at 600 g for five
minutes at 4°C. Following sonication, intact cells were not visible
by microscopic examination. The standard assay mixture in 1 ml of
HEPES/sucrose buffer contained cell homogenate equivalent to 1
X jØ6 cells (100 p.g protein), CaCI2 (1 mM), and lyso-PAF (30
mM). The mixture was preincubated for five minutes at 37°C and
the reaction was started by adding 50 nmol of [3H}acetyl-C0A
(4313 dpm/nmol) in a volume of 50 p.1. After 0 or 15 minutes, the
reaction was stopped by the addition of chloroform/methanol!
water (1:2:0.8) and [3H]PAF was extracted as described above.
3H-PAF production was undetectable at 0 time in the absence of
lyso-PAF and CaCl2. 3H-PAF production increased in a linear
fashion through 30 minutes. Results are expressed as pmols
PAP/mg prot/hr.
In vitro PAF acelyihydrolase activity assay
PAF acetylhydrolase activity in cell lysates was determined by
the method of Stafforini et al [29] and modified by Villani et al
[28]. Cell lysates were prepared as above and resuspended in 0.2%
(wt/vol) BSA and 0.1 HEPES (pH 7.2) and sonicated and
centrifuged as described. Cell-free supernatants (1 ml equivalent
to 1 x 106 cells, 100 p.g protein) were added to polypropylene test
tubes containing 4 nmol (10 p.1) of 1-0-alkyl-2[3H]-acetyl-sn-
glycerol-3-phosphocholine (10 Ci/mmol). Reactions were incu-
bated at 37°C for 0 or 30 minutes and stopped by the addition of
1 ml 10 M acetic acid. Aliquots were applied to individual Sep-Pak
C18 gel cartridges (Waters Associates, Milford, Massachusetts,
USA) which had been activated with 5 ml of ethanol followed by
5 ml of water. After sample addition, the cartridges were washed
twice with 1.5 ml of 0.1 M sodium acetate. These washes were then
transferred to scintillation vials, dried down in a Speed-Vac
Concentrator (Savant, Farmingdale, New York, USA) and resus-
pended in 0.5 ml water. Retained lipids were recovered with a 5
ml wash of chloroform/methanol (1:2, vol/vol). Control experi-
ments indicated that >99% of [3H]acetate and >80% 1-0-
hexadecyl-2[3H]-acetyl-sn-glycero-3-phosphocholine were recov-
ered in the acetate, or chloroform/methanol washes, respectively.
Both [3H]acetate (acetate wash) and [3H]-labeled lipids (chloro-
form/methanol wash) were quantified by liquid scintillation count-
ing. As with the PAP acetyltransferase assay, data is expressed as
pmol/mg protein/hr after the 0 time incubation has been sub-
tracted from the 30 minute incubation. Protein content was
determined by the methods of Lowry et al [30].
Results
Initial studies were conducted to determine whether a cultured,
large T-antigen-transformed, GEC line could incorporate 3H-
acetate into TLC-separated 3H-PAF in the absence or presence of
thrombin. 3H-acetate label was observed only in a region of the
TLC plate that comigrated with authentic PAF. Regions of the
TLC plate that correspond to Rf values associated with lyso PAP,
PtdCho and PtdEth did not incorporate label (no significant
difference from the origin). Thrombin stimulated 3H-acetate
incorporation into 3H-PAF as early as five minutes, gradually
increasing through six hours and remaining elevated up to 24
hours (Fig. 1). Basal incorporation also increased over 24 hours,
suggesting an active basal PAP synthesis in GEC which can be
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Fig. 1. The effects of thrombin (2 U/mi) upon 3H-acetate incorporation into
3H-PAF as a function of time in transformed bovine GEC. N = 8, each N
replicated in duplicate, x SEM. Two-way ANOVA established a signifi-
cant (P < 0.01) difference between thrombin-treated (0) and control ()
groups. If not indicated, the standard error bar is smaller than the
represented icon.
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0.00 0.20 0.40 0.60 0.80 1.00
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Fig. 3. The effects of thrombin (2 U/mi) upon 3H-acetate incorporation into
3H-PAF as a function of time in BPAEC (A) and MC (B). N = 4 for A and
N = 10 for B, each N replicated in duplicate, x SEM. Two-way ANOVA
established a significant difference (P < 0.01) between thrombin-treated
(0) and control (Lx) groups for each cell type, If not indicated, the
standard error bar is smaller than the represented icon.
30 minutes 24 hours
Fig. 2. The effects of thrombin (2 U/mi) upon 3H-acetate incorporation into
3H-aikyl- and 3H-acyl-PAF in transformed rat GEC. The figure depicts
3H-total PAF and 3H-alkyl-PAF formation. The cross-hatched segment of
each bar corresponds to the 3H-alkyl-PAF component. 3H-acyl-PAF
production is the difference between these two values (open-segment for
each bar). PAP analogs were TLC-separated as their diglyceride-acetate
derivatives. N = 3, x SEM, * P< 0.05 for 3H-alkyl-PAF and 3H-total PAF
comparisons between control and thrombin at both time points.
stimulated by thrombin. In data not shown, maximal 3H-PAF
production at 60 minutes was observed with 2 U/mi thrombin as
doses as high as 20 U/mi did not further stimulate 3H-PAF
synthesis. To confirm these data, in another model of transformed
GEC, we assessed the effects of thrombin for either 30 minutes or
24 hours upon PAF synthesis in adenovirus transformed rat GEC
(Fig. 2); 2 U/mI thrombin elevated total PAF production at both
time points. Again, in an analogous fashion to the transformed
bovine GEC line, thrombin stimulated both acute and chronic
PAF production. In addition, baseline PAF production also
increased over the 24-hour incubation period.
We have previously shown in MC, mononuclear phagocytes,
and neural tissue that the material that comigrates with authentic
PAP is indeed bioactive PAF (1-0-alkyl) by platelet aggregation,
3H-serotonin release from platelets and HPLC analysis [25, 28,
31]. To confirm that the TLC-separated lipid that comigrates with
authentic C-18 PAF is indeed bioactive 1-0-alkyl-2-acetyl-glyc-
ero-3 phosphocholine, we derivatized this lipid to its diglyceride-
acetate analog which allows TLC-quantification of acyl-PAF and
alkyl-PAF components. In these experiments, that utilized the
adenovirus transformed rat GEC line, bioactive 1-0-alkyl-PAF
was produced upon thrombin (2 U/mi) stimulation at both time
points (Fig. 2). Even though a majority of total PAF production at
all time points studied is bioactive, 1-0-alkyl PAF; the ratio of
thrombin-stimulated 1-0-alkyl PAP formation to total PAP for-
mation decreased over time (79% at 30 mm and 60% at 24 hr).
In contrast to these GEC data, basal 3H-acetate incorporation
into 3H-PAF did not gradually increase for BPAEC (Fig. 3A) or
MC (Fig. 3B) in culture. In the case of BPAEC, basal PAP
production, while elevated compared to GEC, remained constant
for up to 24 hours and was unresponsive to long-term thrombin
stimulation. Maximal 3H-PAF formation was seen at five minutes
and returned to basal levels after 30 minutes for BPAEC. With
MC, maximal thrombin-stimulated 3H-PAF was observed at one
minute, a second peak was seen at 15 minutes and 3H-PAF
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accumulation returned to basal levels after 60 minutes. These data
suggest that even though thrombin stimulates 3H-PAF in both
endothelial and mesenchymal cell lines, that 3H-PAF synthesis in
GEC is unique and distinct from large vessel endothelial cells
(BPAEC) as thrombin-stimulated PAF formation follows a
chronic rather than an acute pattern in endothelial cells of
glomerular origin.
We next tested the ability of the large T-antigen transformed
bovine GEC line to respond to other mediators with increased
PAF synthesis over an extended period of time. For all subsequent
experiments, the transformed bovine GEC line was utilized.
Bradykinin, like thrombin, induces 3H-acetate incorporation into
3H-PAF over a 24 hour period with an early peak synthesis seen
at 10 minutes (Fig. 4A). Likewise, ATP, endothelin and histamine
elevate 3H-PAF production after 10 minutes and one hour, and
interleukin-1 but not PDGF stimulates 3H-PAF generation at 6
and 24 hours (Fig. 4B-C). These results suggest that this GEC line
is capable of chronic PAF formation induced by various vasocon-
strictors, inflammatory agonists, or cytokines. Endothelial cells do
not possess PDGF receptors [321, and this explains the negative
results with PDGF-stimulated PAF synthesis.
To further dissect out the enzymatic mechanism for the chronic
production of PAF in GEC lines, we developed cell-free assays for
both PAF-acetyl transferase and PAF-acetyl hydrolase activities
in sonicated cell lysates of GEC and compared thrombin-stimu-
lated specific activities in GEC with BPAEC at various time points
(Fig. 5). Confirming the H-acetate incorporation studies, in
BPAEC cells, thrombin-stimulated PAF acetyl transferase dis-
played an acute up-regulation of activity that peaked after 10
minutes and rapidly returned to basal levels. Supporting the
phasic formation of PAF, thrombin-stimulated PAF acetyihydro-
lase activity gradually increased over time and, in fact, exceeded
PAF acetyl transferase activity at three hours in these BPAEC
cells. Substantiating the chronic formation of PAF induced by
thrombin in intact GEC lines, PAF acetyl transferase activity in
these bovine GEC preparations continues to increase over time
and does not peak and return to basal activity as does PAF acetyl
transferase activity from BPAEC preparations. PAF acetyl hydro-
lase activity for GEC preparations was of a similar magnitude as
PAF acetyl hydrolase activity for BPAEC preparations and, at the
two time points studied, was lower than the corresponding PAF
acetyl transferase activity (5 mm, 29 pmol/mg protein/hr; 30 mm,
341 pmol/mg protein/hr). Taken together, these cell free studies
confirm studies using intact cells demonstrating that thrombin-
stimulated PAF production in GEC is chronic rather than acute
and, most likely, reflects a sustained stimulation of PAP acetyl
transferase activity that is maintained for up to one hour.
We as well as others have demonstrated that in certain cell lines
the addition of exogenous lyso-PAF at concentrations that do not
induce cell injury, as assessed by trypan blue exclusion or acridine
orange/ethidium bromide staining, increase receptor-mediated
PAP synthesis, suggesting that a phospholipase A2 or a transacy-
lase activity may be the rate-limiting step in PAF synthesis [25, 33,
34]. To test this hypothesis in GEC lines, we first demonstrated
that during the 10 minutes of the assay, after correction for
extraction efficiency, nearly 30% of the 3H-alkyl lyso PAF inter-
calates into the membrane with an additional 10% of the label
being reacylated into 3H-PAF. Maximal uptake of 3H-alkyl lyso
PAF occurred after five minutes with no further incorporation
noted up to 30 minutes. We utilized an exogenous concentration
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Fig. 4. The effects of various agonists upon 3H-acetate incoiporation into
3H-PAF in transformed bovine GEC. A depicts the effects of bradykinin
(l0_6 M) upon 3H-PAF synthesis as a function of time, N = 3, each N
replicated in duplicate, x SEM. Two-way ANOVA established a signifi-
cant (P < 0.01) difference between bradykinin-treated (•) and control
() groups. B and C depict H-acetate incorporation into 3H-PAF for
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GEC MC MC
Fig. 7. The effects of indomethacin (10 pit) upon thrombin (2 UI ml) (A,
B)- and endothelin (10 M) (C)-stimulated 3H-PAF synthesis in GEC (A)
and MC (B, C). Indomethacin () or sodium carbonate control (•) was
added for 15 minutes prior to a stimulation with either thrombin or
endothelin for an additional 5 minutes in GEC and 30 minutes in MC. N
= 4 or 5 exp, x SEM, * P < 0.05 for comparisons between control +
indomethacin vs. thrombin + indomethacin.
Previous publications demonstrate that GEC, BPAEC and MC
are capable of basal synthesis of prostanoids that can be stimu-
lated by various agonists including thrombin and endothelin. The
major prostanoid product in cultured GEC and MC was PGE2,
while the major product in BPAEC was PG!2 measured as the
metabolite 6-keto-PGF1, [3, 35]. The interactions between throm-
bin-stimulated prostanoid and PAF synthesis have not been
investigated. Initially, we assessed thrombin as well as endothelin-
stimulated PAF synthesis in GEC and MC treated with or without
indomethacin. For both endothelial and mesenchymal cell lines,
indomethacin elevated both endothelin- and thrombin-mediated
PAF synthesis (Fig. 7), suggesting that prostanoid products may
down-regulate PAF synthesis. To confirm these results, exogenous
mimetics of prostanoids of the E and I series were added to MC
cultures stimulated with thrombin (Fig. 8). Both 16,16-dimethyl
PGE2 and iloprost, a PG!2 mimetic, decreased thrombin-stimu-
lated but not basal PAF synthesis in a dose-dependent manner,
suggesting that anti-inflammatory prostanoids may, in part, exert
their effects through diminishing the formation of the inflamma-
tory bioactive lipid, PAF.
Taken together, the data suggest that GEC lines in culture have
both an active basal and agonist-stimulated PAF synthetic capa-
bility. In addition, in contrast to BPAEC which transiently form
PAF in response to agonists, GEC lines are capable of sustaining
long-term PAF responses that persist upwards to 24 hours post-
stimulation. One potential mechanism to curtail the chronic
formation of PAF in GEC or MC may be the concomitant
formation of anti-inflammatory prostanoids which may diminish
receptor-mediated PAF formation.
Discussion
Utilizing two separate transformed cell lines of GEC, we have
characterized basal and thrombin-stimulated PAF synthesis in
whole cells and in cell-free assays. We have shown that GEC lines
constitutively synthesize PAF and that thrombin stimulation aug-
ments PAF synthesis which can be sustained for upwards of 24
hours. This is in direct contrast to BPAEC and MC in which basal
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Fig. 5. The effects of thrombin (2 U/mi) upon PAF acelyl transferase and
PAF acetyl hydrolase activities in GEC and BPAEC. Cell lysates were
prepared from control- or thrombin-treated GEC or BPAEC and enzyme
activity was assessed over a 15 minute. (PAF acetyl transferase) or 30
minute (PAF acetyl hydrolase) period. Data were expressed as pmol PAF
formed or degraded/mg protein/hr. Control preparation of BPAEC and
GEC displayed minimal PAF acetyl transferase or acetyl hydrolase activity
that did not change with time (PAF-AT-GEC 3-40; PAF-AT-BPAEC
6-70; PAF-AR-GEC 29-31; PAF-AH-BPAEC 8-37 pmol/mg protein/hr)
and these values were subtracted from corresponding thrombin-stimu-
lated preparations. N = 2 to 5 experiments, each N in duplicate x = SEM.
Symbols are: (U) GEC acetyl transferase; (•) BPAEC acetyl transferase;
(A) BPAEC acetyl hydrolase.
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Fig. 6. The effects of exogenous lyso-PAF (30 pit) upon ATP (A) (10-sM)
or bradykinin (B) (10 M)-stimulated 3H-PAF synthesis in GEC. Lyso-PAF(0) or BSA control (0) was added for 1 minute prior to a 10 minute
stimulation with either ATP, bradykinin or control. N = 4,x SEM, *J
0.05.
of 30 LM lyso-PAF, which results in an effective concentration of
approximately 10 ILM, a dose previously shown to augment PAF
production. Using ATP- or bradykinin-stimulated GEC, agonists
that resulted in maximal PAF synthesis at 10 minutes, we ob-
served that exogenous lyso-PAF did not further (significantly)
increase ATP- or bradykinin-mediated PAF synthesis (Fig. 6).
This suggests but does not prove that the rate-limiting step in
agonist-stimulated GEC PAF synthesis may be PAF acetyl trans-
ferase and not the availability of alkyl lyso glycero phosphocholine
substrate.
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Fig, 8. The effects of exogenous 16-16 dimethyl PGE2 (A) or the PG!2
mimetic, iloprost (B), upon thrombin (2 U/ml)-stimulated 3H-PAF synthesis
in MC as a function of dose. Various doses of POE2, iloprost or BSA
control were added 5 minutes prior to addition of thrombin and then
3H-acetate incorporation into 3H-PAF was assessed after an additional 15
minutes. N = 4, x SCM, *P < 0.05.
PAF synthetic activity is minimal and thrombin stimulates an
acute, transient production of PAF. We have verified a chronic
pattern of PAF synthesis in two separate GEC lines transformed
by entirely different procedures. The simian virus large T antigen
was used to transform bovine GEC, while the adeno virus was
used to infect and immortalize rat glomeruli and a GEC line was
cloned from these transformed glomeruli. Thus, we argue that the
chronic production of PAF evident in both GEC lines is more
likely an intrinsic feature of GEC lines and probably minimally
due to transformational or cultural influences. We suggest that
transformed GEC lines are a better model than untransformed
primary cultures of GEC as culturing of primary cultures results in
loss of the endothelial phenotype. Further evidence to support the
contention that transformation process is not the primary modu-
lator of chronic PAF production is provided by untransformed
PMA-differentiated U957 monocytes which have been shown to
respond to respiratory synctial virus with a chronic up-regulation
of PAF production [28]. As a comparison macrovascular endo-
thelial cell, we have utilized BPAEC, a cell that, while not
transformed, is immortal in the sense that it does not lose its
endothelial phenotype after multiple passages.
In almost all cases, agonist-stimulated PAF synthesis is an acute
reaction in micro- and macro-vessicular endothelial cells. More-
over, basal PAF synthesis is minimal in endothelial cells. For
example, endothelium from diverse vascular sources (aorta, pul-
monary artery, coronary, vena cava) produce stimulated peak
concentrations of PAF within 20 minutes [36]. Moreover, in
human umbilical vein endothelial cells, thrombin stimulates a
rapid PAF response within seconds which subsides within 30
minutes [37]. Other inflammatory agents besides thrombin, in-
cluding bradykinin, histamine and IL-la, also induce a sustained
PAF production in the bovine GEC line. IL-la induced PAF
synthesis only after six hours and might reflect an induction of
PAY acetyltransferase as previously noted for both IL-la and
TNF [38]. Time course kinetic experiments for in vitro PAF
acetyltransferase experiments in HUEVC and BPAEC reveal a
rapid stimulation of enzyme activity that subsides within 30
minutes, mimicking the intact cell experiments [5, 39], thus
supporting our contention that PAF acetyltransferase may be the
rate limiting step for PAY synthesis in these endothelial cell lines.
We have suggested but have not proven that the rate limiting step
for PAY synthesis in GEC may be PAY acetyltransferase, since
exogenous lyso-PAY does not increase agonist-stimulated PAY
synthesis, thus potentially ruling out a phospholipase A2 or a
transacylase activity [33, 34]. However, the role of agonist-
stimulated PLA2 to regulate PAY synthesis in GEC lines deserves
further study. Our results are in agreement with studies that
utilize human umbilical vein endothelial cells and noted that
exogenous lyso PAY did not affect PAY production [26]. In these
findings, lyso PAY, at a similar concentration, was acylated and
thus could be used as a potential substrate for transacylation
and/or acetylation.
Similar rapid and acute kinetics for formation of PAY have also
been noted in stimulated monocytes, macrophages and mesangial
cells [25, 40, 41]. Mesangial cells stimulated with either A23187 or
endotoxin respond with a gradual increase of PAY production that
peaks at three hours and then diminishes towards baseline values
[25, 41]. In contrast to activated macrophages or mesangial cells,
endothelial-derived PAY is completely cell-retained [5]. More-
over, the predominant species of endothelial cell-derived PAY
may be the 1-0-acyl and not the 1-0-alkyl form of PAY [42, 43].
Utilizing both thrombin-stimulated HUVEC and BPAEC, 90% of
newly synthesized PAY is the 1-0-acyl species which is 1/100 as
active as 1-0-alkyl PAY species [42, 43]. Our studies suggest that,
in contrast to macro-vascular endothelial cells, the adeno-virus
transformed GEC line synthesized predominantly bioactive alkyl
PAY. These data again strongly argue for a pathophysiological
role of PAY in the diseased glomerulus. In support of these
findings, A23187-stimulated HUVEC produce alkyl but not acyl
PAY species [44], suggesting specific agonist-mediated pools of
lysophospholipids coupled to acetyltransferase activity.
Very few stimuli have been shown to down-regulate or decrease
PAY synthesis. PAY synthesis (basal or agonist-stimulated) has
been shown to be decreased by anti-inflammatory prostaglandins.
P012 inhibits PAY release in PMN leukocytes [45].POE2 reduces
LPS-stimulated PAY synthesis in duodenum but not stomach
tissue [46]. Free arachidonate also diminishes A23187-stimulated
PAY synthesis in PMN [47]. Anti-inflammatory prostaglandins
often exert their biological functions through stimulation of
adenylate cyclase and production of cAMP. Forskolin, an activa-
tor of adenylate cyclase, inhibits A23 187-stimulated PAY produc-
tion in mouse mast cells [48], and forskolin as well as iloprost
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inhibit PAF acetyltransferase in HUEVC [39]. In additiol3, dibu-
tyryl cAMP inhibits antibody-activated PAF synthesis in bsophil-
rich rabbit leukocyte preparations [49] and reduces PAF synthesis
in mast cells [48]. It is suggested that the modulation of PAF
synthesis by anti-inflammatoiy prostaglandins may provide an
endogenous negative feedback loop, as newly synthesized PAF in
GEC may act as an autocrine agent stimulating prostaglandin
synthesis. In this regard, PAF-receptor-mediated responses in-
cluding nitric oxide synthesis have been demonstrated in GEC [3].
In contrast to most endothelial cells, GEC lines respond to
thrombin with a sustained increase in bioactive PAF production
rather than a transient spike of PAF synthesis. The significance of
this chronic stimulation of PAF in the glomerulus may regulate
PAF-dependent events such as thrombin-activated GEC matrix
production, cell-cell communication and/or mitogenesis. For ex-
ample, both thrombin and PAF stimulate matrix formation and
interactions [13, 50]. Sustained PAF formation may also augment
GEC interactions with PMN, macrophages and platelets in patho-
logical glomeruli. It has been postulated that endothelial cells
activated by inflammatory or thrombotic agonists synthesize PAF
which is expressed on the endothelial cell surface, and mediate
interactions with PAF receptors on circulating cells [14, 16, 51].
Finally, chronically-stimulated PAF formation induced by throm-
bin may induce proliferation of endothelial cells in an autocrine
fashion or influence proliferation of vascular smooth muscle cells
or mesangial cells. Thrombin induces endothelial proliferation
[52] and PAF stimulates mitogenesis in vascular smooth muscle
[53] and in bone marrow cells [54]. Thus, in conclusion, due to the
confined environment of the glomerulus, sustained production of
PAP may have profound long-term effects on glomerular cells
through autocrine or paracrine mechanisms as significant concen-
trations of PAF may accumulate. Also, chronic PAF production
by GEC may augment or exacerbate acute PAF synthesis from
activated MC. To regulate this orchestrated production of PAF in
the glomerulus, concomitant synthesis of anti-inflammatory pros-
tanoids may down-regulate agonist-stimulated PAF synthesis.
These observations may help explain the therapeutic benefit of
treatment with PGE2 and PGE2 analogs in diverse models of
renal injury including mice with lupus erythematosus and mice
and rats with immune complex forms of glomerulonephritis [55].
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Appendix. Abbreviations
platelet-activating factor
glomerular endothelial cells
bovine pulmonary aortic endothelial cells
mesangial cells
bovine calf serum
physiologically buffered saline
low density lipoprotein
phosphatidylcholine
phosphatidylethanolamine
dithiothreitol
ethylene glycol-bis-(beta-aminoethyl ether)
N,N,N,N'-tetra-acetic acid
N-(2-hydroxy-ethyl)-1-piperazine-ethane sulfonic
acid
1-0-steatyl-sn-glycero-3-phosphocholine
PAF acetyl transferase
PAF acetyl hydrolase
human umbilical vein endothelial cells
bovine serum albumin
prostaglandin E2
polymorphonuclear leukocyte
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